Study Indicates Potential of Pembrolizumab in Advanced Melanoma : vimarsana.com

A change in recurrence-free survival was also observed, with an 89% rate at 24 months in patients who achieved a complete pathologic response.

Related Keywords

Texas , United States , Victor Prieto , Sapna Patel , Neoadjuvant Pembrolizumab , University Of Texas Md Anderson Cancer Center , National Cancer Institute , Phyllis Gyorkey Research , New England Journal , Cancer Center , Adjuvant Versus Neoadjuvant Pembrolizumab , Clinically Detectable Stage , National Cancer ,